Levetiracetam Injection, Solution, Concentrate
Product Images NDC 39822-4000

12 FDA label images from Xgen Pharmaceuticals Djb, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 39822-4000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xgen Pharmaceuticals Djb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation 1 (Levetiracetam Injection 1)

Equation 1 (Levetiracetam Injection 1)
A formula for calculating the total daily dose in mL/day. It divides the product of daily dose (mg/kg/day) and patient weight (kg) by 100 mg/mL to determine the dosage volume.*
FDA Label Image

Equation 2 (Levetiracetam Injection 2)

Equation 2 (Levetiracetam Injection 2)
A formula expressing creatinine clearance (CLcr) calculation: [(140 - age in years) multiplied by weight in kilograms] divided by [72 multiplied by serum creatinine in mg/dL], with a multiplier of 0.85 for female patients. This formula is commonly used in clinical settings.*
FDA Label Image

Equation 3 (Levetiracetam Injection 3)

Equation 3 (Levetiracetam Injection 3)
A formula diagram showing the calculation of creatinine clearance (CLcr) normalized for body surface area (BSA). The formula is CLcr (mL/min/1.73m²) equals the creatinine clearance in mL/min divided by the subject's BSA in m², then multiplied by 1.73.*
FDA Label Image

Molecular Formula (Levetiracetam Injection 4)

Molecular Formula (Levetiracetam Injection 4)
Chemical structure of levetiracetam, showing the molecular arrangement of atoms including a pyrrolidone ring and attached ethyl and amide groups, consistent with its pharmaceutical composition.*
FDA Label Image

Fig 1 (Levetiracetam Injection 5)

Fig 1 (Levetiracetam Injection 5)
A bar chart comparing the percentage of patients responding to Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The Y-axis represents the percentage of patients from 0% to 40%. Placebo shows 7.4%, Levetiracetam 1000 mg/day shows 37.1%, and Levetiracetam 3000 mg/day shows 39.6%. An asterisk denotes statistically significant differences versus placebo for both Levetiracetam doses.*
FDA Label Image

Fig 2 (Levetiracetam Injection 6)

Fig 2 (Levetiracetam Injection 6)
A bar graph showing the percentage of patients by treatment group: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). The chart includes notation of statistical significance versus placebo for the Levetiracetam groups.*
FDA Label Image

Fig 3 (Levetiracetam Injection 7)

Fig 3 (Levetiracetam Injection 7)
A bar graph comparing the percentage of patients experiencing an outcome in two groups: placebo (14.4% of 104 patients) and Levetiracetam 3000 mg/day (39.4% of 180 patients). The Levetiracetam group shows a statistically significant difference versus placebo as indicated by an asterisk.*
FDA Label Image

Fig 4 (Levetiracetam Injection 8)

Fig 4 (Levetiracetam Injection 8)
Bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=97) shows 19.6% of patients, while the Levetiracetam group (N=101) shows 44.6% of patients. An asterisk indicates a statistically significant difference versus placebo.*
FDA Label Image

Fig 5 (Levetiracetam Injection 9)

Fig 5 (Levetiracetam Injection 9)
Bar chart comparing the percentage of patients in two groups: Placebo (19.6%, N=51) and Levetiracetam (43.1%, N=58). The figure includes a note indicating statistical significance of Levetiracetam versus placebo.*
FDA Label Image

Fig 6 (Levetiracetam Injection 10)

Fig 6 (Levetiracetam Injection 10)
A bar graph comparing the percentage of patients between two groups: Placebo (N=84) with 45.2% and Levetiracetam (N=79) with 72.2%. The graph indicates a statistically significant difference between the Levetiracetam group and the placebo group as noted by an asterisk.*
FDA Label Image

Lvt-bdr-vl-00 (Lvt Bdr Vl 00)

Lvt-bdr-vl-00 (Lvt Bdr Vl 00)
Levetiracetam Injection 500 mg/5 mL (100 mg/mL) intravenous solution concentrate in a 5 mL single-dose vial. Label indicates the product must be diluted before administration. Manufactured by XGen Pharmaceuticals DJB, Inc., Big Flats, NY, with storage instructions at 20º-25ºC. Includes barcode and handling instructions.*
FDA Label Image

Lvt-bdr-cm-00 (Lvt Bdr Cm 00)

Lvt-bdr-cm-00 (Lvt Bdr Cm 00)
Levetiracetam Injection 500 mg/5 mL (100 mg/mL) intravenous solution concentrate carton label from XGen Pharmaceuticals DJB, Inc. The label states it contains 10 single-dose 5 mL vials and must be diluted prior to administration. It includes storage instructions and manufacturing info, with NDC 39822-4000-1 visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.